8.475

2.72% 0.205

CorMedix Inc (CRMD)

Overview News Price History Option Chain Discussions Forecast Stock Split

CorMedix Inc stock is traded at $8.475, with a volume of 439.94K. It is up +2.72% in the last 24 hours and up +8.63% over the past month. CorMedix, Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix, Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.

Previous Close:

$8.27

Open:

$8.29

24h Volume:

439.94K

Relative Volume:

0.33

Market Cap:

$664.10M

Revenue:

$311.71M

Net Income/Loss:

$163.05M

P/E Ratio:

4.2728

EPS:

1.9835

Net Cash Flow:

$172.79M

1W Performance:

+7.12%

1M Performance:

+8.63%

6M Performance:

-11.97%

1Y Performance:

-32.20%

1-Day Range:

$8.25

$8.535

1-Week Range:

$7.77

$8.535

52-Week Range:

$6.125

$17.43

CorMedix Inc Stock (CRMD) Company Profile

Name

CorMedix Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

908-517-9500

Address

400 Connell Drive, 5th Floor, Suite 5000, Berkeley Heights, NJ

Employee

Twitter

Next Earnings Date

2026-05-14

Latest SEC Filings

CRMD's Discussions on Twitter

Compare CRMD vs VRTX, REGN, ARGX, ALNY, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CRMD CorMedix Inc	8.465	648.80M	311.71M	163.05M	172.79M	1.9835
VRTX Vertex Pharmaceuticals Inc	442.19	110.64B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	630.88	66.53B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	823.05	50.27B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	294.80	39.45B	4.29B	577.22M	641.34M	4.2086
RVMD Revolution Medicines Inc	152.44	32.93B	742.00K	-1.37B	-1.07B	-7.0731

CorMedix Inc Stock (CRMD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Oct-20-25	Upgrade	D. Boral Capital	Hold → Buy
Jun-30-25	Downgrade	D. Boral Capital	Buy → Hold
Jun-30-25	Initiated	H.C. Wainwright	Buy
Mar-07-25	Initiated	Leerink Partners	Outperform
Jan-13-25	Initiated	D. Boral Capital	Buy
Aug-26-24	Initiated	Rodman & Renshaw	Buy
Aug-10-23	Initiated	RBC Capital Mkts	Outperform
Feb-17-21	Initiated	Needham	Buy
Sep-29-20	Initiated	JMP Securities	Mkt Outperform
Sep-21-20	Initiated	Truist	Buy
Dec-18-19	Initiated	B. Riley FBR	Buy
Mar-26-19	Reiterated	H.C. Wainwright	Buy
Dec-06-18	Initiated	ROTH Capital	Buy
Sep-25-17	Reiterated	H.C. Wainwright	Buy
Aug-10-17	Reiterated	Rodman & Renshaw	Buy
May-05-17	Reiterated	Rodman & Renshaw	Buy
Nov-11-16	Reiterated	FBR & Co.	Outperform
Mar-17-16	Reiterated	FBR Capital	Outperform
Mar-03-16	Initiated	FBR Capital	Outperform
Nov-16-15	Reiterated	ROTH Capital	Neutral
Oct-29-15	Reiterated	ROTH Capital	Neutral
May-06-15	Downgrade	ROTH Capital	Buy → Neutral
Dec-08-14	Reiterated	ROTH Capital	Buy
Oct-03-11	Downgrade	Maxim Group	Buy → Hold

View All

CorMedix Inc Stock (CRMD) Latest News

May 25, 2026

CorMedix eyes REZZAYO expansion as DefenCath reimbursement shift looms - MSN

May 25, 2026

May 24, 2026

Cormedix outlines $325M-$345M 2026 net revenue outlook amid TDAPA transition - MSN

May 24, 2026

CorMedix Q1 earnings call highlights - MSN

May 24, 2026

May 22, 2026

CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets - TradingView

May 22, 2026

CRMD Q1 earnings beat on DefenCath momentum, guidance raised - MSN

May 22, 2026

CorMedix Eyes REZZAYO Expansion as DefenCath Reimbursement Shift Looms - MarketBeat

May 22, 2026

CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD) - Seeking Alpha

May 18, 2026

HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD) - MarketBeat

May 18, 2026

May 17, 2026

Does Strong Q1 Beat And Raised Outlook Transform The Bull Case For CorMedix (CRMD)? - Yahoo Finance

May 17, 2026

May 16, 2026

The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results - simplywall.st

May 16, 2026

A Look At CorMedix (CRMD) Valuation After Strong Q1 2026 Results And Raised Full Year Guidance - Yahoo Finance

May 16, 2026